Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation

被引:2
|
作者
Abay, Merve [1 ]
Ozgen, Levent [1 ]
Yalcin, Yakup [1 ]
Ozerkan, Kemal [1 ]
机构
[1] Uludag Univ, Fac Med, Gynecol Oncol Surg, TR-16059 Bursa, Turkiye
关键词
BRCA; 1/2; Ovarian carcinoma; Serous tubal intraepithelial carcinoma; Risk reducing salpingo-oophorectomy; FOLLOW-UP; CANCER; CARRIERS; OVARIAN; OUTCOMES; SURGERY;
D O I
10.1016/j.jogoh.2023.102642
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion which is located in the distal fallopian tube and causes high grade serous ovarian carcinoma (HGSOC). The incidence of STIC for women underwent risk reducing salpingo-oophorectomy for BRCA mutation varies from 0.6 to 7% and its clinical outcomes are still unclear. The aim of this study was to demonstrate the incidence of STIC and HGSOC in BRCA1/2 mutation carriers after risk reducing salpingo-oophorectomy (RRSO) and the clinical outcomes of these patients. Material and methods: We retrospectively reviewed the records of 48 BRCA1 and/or 2 mutation carriers who underwent prophylactic salpingo-oophorectomy with or without hysterectomy at the Department of Obstetrics and Gynecology, Bursa Uludag University between January 2000 and January 2022. Inclusion criteria: BRCA 1 and/or 2 mutation carriers diagnosed by genetic testing, asymptomatic patients with no abnormal findings on pelvic examination. Exclusion criteria: patients with no abnormal findings on pelvic examination and a presence of a personal history of ovarian, fallopian tube or peritoneal cancer. Results: A total of 48 BRCA 1 and/or 2 mutation carriers underwent RRSO. STIC was diagnosed in 1 (2,0%) patient and restaging surgery was not performed. Primary peritoneal carcinoma (PPC) did not develop during the 20 months follow-up period. One (2.0%) patient was diagnosed with occult ovarian cancer. Restaging surgery was performed and chemotherapy treatments were given after surgery. A pelvic recurrence developed 25 months after the occult cancer diagnosis in the follow up period. One (2.0%) patient with normal histopathological findings after RRSO was diagnosed with peritoneal cancer 57 months after the operation. Conclusion: The risk of PPC continues after RRSO. Therefore, close follow-up procedure is very important for early diagnosis and effective treatment of patients with PPC after RRSO.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers
    Kerstin Rhiem
    Dolores Foth
    Barbara Wappenschmidt
    Heidrun Gevensleben
    Reinhard Büttner
    Uwe Ulrich
    Rita K. Schmutzler
    Archives of Gynecology and Obstetrics, 2011, 283 : 623 - 627
  • [2] RISK-REDUCING SALPINGO-OOPHORECTOMY IN BRCA MUTATION PATIENTS
    Loizzi, Vera
    Arezzo, Francesca
    Mongelli, Michele
    Kardhashi, Anila
    Silvestris, Erica
    Cazzolla, Ambrogio
    Difonzo, Tommaso
    Cerbone, Marco
    Battista, Gaia
    Quarto, Pietro
    Memmola, Massimiliano
    Cormio, Gennaro
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A342 - A342
  • [3] Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers
    Rhiem, Kerstin
    Foth, Dolores
    Wappenschmidt, Barbara
    Gevensleben, Heidrun
    Buettner, Reinhard
    Ulrich, Uwe
    Schmutzler, Rita K.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 283 (03) : 623 - 627
  • [4] Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff, ND
    Satagopan, JM
    Robson, ME
    Scheuer, L
    Hensley, M
    Hudis, CA
    Ellis, NA
    Boyd, J
    Borgen, PI
    Barakat, RR
    Norton, L
    Offit, K
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21): : 1609 - 1615
  • [5] Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers
    Kara N. Maxwell
    Susan M. Domchek
    Current Breast Cancer Reports, 2012, 4 (3) : 199 - 206
  • [6] Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers
    Maxwell, Kara N.
    Domchek, Susan M.
    CURRENT BREAST CANCER REPORTS, 2012, 4 (03) : 199 - 206
  • [7] Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation
    Jung, Sung Mi
    Ryu, Jai Min
    Park, Hyung Seok
    Park, Ji Soo
    Kang, Eunyoung
    Lee, Seeyoun
    Lee, Han-Byoel
    Youn, Hyun Jo
    Yoo, Tae-Kyung
    Kim, Jisun
    Lee, Jeong Eon
    Han, Sang Ah
    Kim, Dongwon
    Kim, Sung-Won
    JOURNAL OF BREAST CANCER, 2020, 23 (06) : 647 - 655
  • [8] Risk-reducing salpingo-oophorectomy for BRCA mutation carriers
    Haldar, Krishnayan
    Crawford, Robin
    MATURITAS, 2010, 67 (03) : 290 - 290
  • [9] Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2
    Kauff, Noah D.
    Barakat, Richard R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) : 2921 - 2927
  • [10] No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers
    van Bommel, Majke H. D.
    de Jong, Marieke Arts
    Steenbeek, Miranda P.
    Bots, Michiel L.
    van Westerop, Liselore L. M.
    Hopman, Maria T. E.
    Hoogerbrugge, Nicoline
    de Hullu, Joanne A.
    Maas, Angela H. E. M.
    JOURNAL OF CARDIOLOGY, 2021, 77 (06) : 570 - 575